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 Introduction 
 Natural killer (NK) cells are an important constituent 
of the innate immune system, exert cytotoxicity against 
infected and transformed cells, and produce cytokines 
and chemokines that regulate adaptive immune respons-
es  [1–3] . In humans, NK cell function is regulated by clon-
ally distributed inhibitory receptors termed killer cell im-
munoglobulin-like receptors (KIR). KIR recognize epi-
topes (KIR ligands) shared by human leukocyte antigen 
(HLA) class I antigens. Functional NK cells express at 
least one receptor for self HLA class I. Those which ex-
press, as their only inhibitory receptor for self, a KIR for 
the HLA class I group which is absent on allogeneic tar-
gets sense the missing expression of the self class I KIR 
ligand and mediate alloreactions  [4–10] .
 Donor-versus-recipient NK cell alloreactions may oc-
cur in HLA haplotype mismatched (haploidentical) he-
matopoietic stem cell transplantation (HSCT) with KIR 
ligand incompatibility in the graft-versus-host direction. 
NK cell alloreactivity impacts beneficially on outcome 
after haploidentical transplants  [11, 12] , as it reduces the 
risk of leukemia relapse without causing graft-versus-
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 Abstract 
 The main functions of natural killer (NK) cells are early pro-
tection against viruses or tumor cells and production of cy-
tokines that regulate immune functions. The present study 
assessed the role of different NK subsets in exerting graft-
versus-leukemia effects in recipients of human leukocyte an-
tigen (HLA) haploidentical hematopoietic transplants and 
monitored for the first time CD3–/CD56– lymphocyte ex-
pansion. CD3–/CD56– cells expressed NK cell-associated 
molecules, such as CD16, NKp46, NKp30, CD244 (2B4), CD161, 
and killer cell immunoglobulin-like receptors. CD3–/CD56– 
cells further exhibited the classical functional characteristics 
of NK cells: cytolysis of target cells lacking HLA class I, anti-
body-dependent cellular cytotoxicity and cytokine produc-
tion. These results demonstrate that CD56– NK cells are func-
tional, recognize missing self and, like their CD56+ counter-
parts, may contribute to graft-versus-leukemia reactions. 
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host disease, and thereby markedly improves leukemia-
free survival in humans and in murine models  [13–16] . 
 In our studies on the NK cell repertoire reconstitution 
pattern in haploidentical HSCT recipients, we detected ex-
pansion of an unusual KIR-expressing CD16+/CD56– NK 
cell subset. Here, we describe its phenotype, posttransplant 
recovery kinetics, function and alloreactive potential.
 Materials and Methods 
 Patients 
 Fifty haploidentical HSCT recipients were included in this 
study. Approval was obtained from the Umbria Region Ethics 
Committee and from the Perugia University institutional review 
board. Informed consent was provided in accordance with the 
Declaration of Helsinki. Diagnoses were acute myeloid leukemia 
in 27 patients, acute lymphoblastic leukemia in 12, Hodgkin’s 
lymphoma in 7, non-Hodgkin’s lymphoma in 2, chronic myeloid 
leukemia in 1 and multiple myeloma in 1. Patients received CD34-
selected peripheral blood hematopoietic stem cell grafts after con-
ditioning with total body irradiation, thiotepa, fludarabine and 
either antithymocyte globulin or the monoclonal anti-CD3 anti-
body OKT3. No pharmacological immunosuppression was given 
after transplantation.
 Flow Cytometry and Immunophenotyping 
 To study reconstituting NK cell subsets after transplantation 
we performed immunofluorescence analyses on NK cells purified 
by the RosetteSep human NK cell enrichment cocktail method 
(StemCell Technologies, Vancouver, B.C., Canada) which consis-
tently allowed purification of a population  1 99% negative for 
CD3+ T lymphocytes (representative plot in  fig.  1 a), CD19+ B 
lymphocytes, CD66b+ granulocytes and CD36+ monocytes.
 To characterize purified NK cells, APC-conjugated anti-CD56 
(IgG1; Miltenyi, Bergisch-Gladbach, Germany) was used in com-
bination with either: unconjugated anti-CD16 (IgM; BD Biosci-
ence, San Jose, Calif., USA) developed with fluorescein isothio-
cyanate (FITC)-conjugated IgM (Southern Biotech, Birmingham, 
Ala., USA) and phycoerythrin (PE)-conjugated anti-NKp46 
(IgG1; Beckman Coulter, Fullerton, Calif., USA); PE-conjugated 
anti-NKp30 (IgG1; Beckman Coulter); PE-conjugated anti-
CD244 (2B4, IgG1; eBioscience, San Diego, Calif., USA); PE-con-
jugated anti-CD161 (NKR-P1A, IgG2a; Miltenyi); (PE)-conjugat-
ed anti-KIR2DL2,3/S2, anti-KIR2DL1/S1 and anti-KIR3DL1/S1 
(all IgG1 from Beckman Coulter) as well as unconjugated anti-
NKG2A (IgG2b, kindly donated by A. Moretta, University of Ge-
noa, Italy) developed with FITC-conjugated goat anti-mouse Ig-
G2b antibodies (Southern Biotech); unconjugated anti-NKp80 or 
unconjugated anti-NKG2D (IgG1, kindly donated by A. Moretta, 
University of Genoa, Italy) developed with FITC-conjugated goat 
anti-mouse IgG1 antibodies (Southern Biotech).
 Enumeration of KIR+/NKG2A–/CD3–/CD56– and KIR+/
NKG2A–/CD3–/CD56+ NK cells was determined from periph-
eral blood mononuclear cells by four-color immunofluorescence 
using the antibodies described above in conjunction with PE-
Cy7-conjugated anti-CD3 (IgG1; eBioscience).
 HLA Missing Self-Response and ADCC 
 To assess missing self-HLA response in CD56+ and CD56– 
NK cells, purified NK cells were incubated with the HLA-defi-
cient erythroleukemia cell line K562. The capacity for ADCC was 
measured by co-incubating purified NK cells with the EBV-trans-
formed B cell line W00 (which expresses all relevant KIR ligands) 
in the presence of saturating concentrations of the chimeric IgG 
anti-CD20 antibody (Rituximab; Roche, Basel, Switzerland). The 
NK cell response in both assays was measured by assessing IFN-  
secretion (by intracellular cytokine staining) and degranulation 
(by assessing surface CD107a)  [17] . As negative controls we co-
incubated NK cells with autologous phytohemagglutinin (PHA) 
lymphoblasts (degranulation and IFN-  production  ! 1% in both 
CD56+ and CD56– subsets); positive controls were effector cells 
with PMA/ionomycin (degranulation and IFN-  production 
 1 30% in both subsets).
 NK Cell Cloning and Cytotoxicity Assay 
 NK cells were separated into CD56+ and CD56– subsets by im-
munomagnetic sorting using PE-conjugated anti-CD56 antibod-
ies and anti-PE antibody-conjugated microbeads (Miltenyi). Pu-
rity of subfractions, as assessed by flow cytometry, was  1 95% for 
CD56+ and  1 99% for CD56– cells. CD56+ and CD56– NK cells 
were plated in 96-well round-bottom plates at concentrations of 
20, 10 and 5 cells/well, activated with PHA (Biochrom KG, Berlin, 
Germany) and cultured with IL-2 (Chiron BV, Amsterdam, The 
Netherlands) on irradiated feeder cells for 3 weeks. Specific lysis 
by cloned NK cells was tested by standard  51 Cr release assay using 
an effector-target ratio of 5: 1 against K562 cells, KIR ligand-mis-
matched allogeneic PHA lymphoblasts, autologous PHA lympho-
blasts and leukemic blasts in selected patients. In tests against KIR 
ligand-mismatched target cells, mean lysis of alloreactive clones 
only (specific lysis  1 5%) within the donor’s repertoire is reported.
 Statistical Analyses 
 Characteristics of CD56+ and CD56– NK cells were compared 
by the Mann-Whitney U test (unpaired comparisons) and Wil-
coxon’s rank test (paired comparisons), where appropriate. Two-
sided p values of  ! 0.05 were considered statistically significant.
 Results 
 Identification of NK Subsets Reconstitution in 
Recipients of Haploidentical Transplantation 
 Flow-cytometric  analyses of reconstituting NK cells 
in recipients of T cell-depleted haploidentical HSCT re-
vealed an unusual subset of CD3– lymphocytes express-
ing KIR but not CD56 molecules ( fig. 1 b). Upon further 
investigation, these CD56– cells expressed NK cell-asso-
ciated and NK cell-specific surface antigens such as 
CD16, 2B4 (CD244), NKR-P1A (CD161) as well as the nat-
ural cytotoxicity receptors NKp30 and NKp46 ( fig. 1 c–e 
show representative flow-cytometric plots). Compared to 
their CD56-expressing counterparts, CD56– NK cells ex-
pressed CD16, KIR and CD161 at similar frequencies, 
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whereas the expression of NKG2A, NKp46, NKp30 and 
2B4 was significantly lower in CD56– compared to 
CD56+ NK cells ( table 1 ).
 As expression of multiple KIR identifies a subset of 
very mature NK cells, we analyzed both overall KIR 
expression and co-expression of multiple KIR. While 
overall expression of KIR was similar between the two 
subsets, expression of more than one KIR was higher in 
CD56+ NK cells than in CD56– NK cells, although 
this difference reached statistical significance only for 
one combination of KIR: KIR2DL1/S1+/KIR2DL2,3/S2+ 
(19  8 18% vs. 6  8 6.6%, p = 0.015), KIR2DL2,3/S2+/
KIR3DL1/S1+ (11  8 11% vs. 3.2  8 3%, p = 0.06) and 
KIR2DL1/S1+/KIR3DL1/S1+ (5.2  8 4.3% vs. 1.6  8 1.7%, 
p = 0.10).
 In an attempt to identify a marker that detects the larg-
est possible number of NK cells in transplant recipients, 
we evaluated several candidate antigens with a broad ex-
105
104
103
0
105
104
103
0
105
104
103
0
105
104
103
0
105
104
103
0
0 102 103 104 105
0 102 103 104 105 0 102 103 104 105
0 102 103 104 105 0 102 103 104 105
CD
3
KI
R
N
Kp
46
CD
16
2B
4
CD56
CD56 CD56
CD56 CD56
0.1
22.0
10.0 35.7
50.5
14.9 67.5
17.6
83.0
0.7
0.53.9
14.0 83.0
1.0
15.0
1.32.0
0.0
78.0
a
b
d e
c
 Fig. 1. Immunophenotype of CD56+ and 
CD56– NK cells after T cell-depleted hap-
loidentical HSCT.  a Detection of a CD56–/
CD3– population after NK cell purifica-
tion.  b– d Expression of KIR ( b ), CD16 ( c ), 
NKp46 ( d ) and 2B4 (CD244;  e ) on CD56– 
and CD56+ NK cells in patients after T 
cell-depleted haploidentical HSCT. All 
analyses carried out on RosetteSep-puri-
fied NK cells. 
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pression on NK cells. On total NK cells, NKp46 was de-
tected in a mean of 83% ( 8 24%), CD244 (2B4) in 99% 
( 8 1%), NKG2D in 91% ( 8 6%), and NKp80 in 94% ( 8 4%). 
Therefore, some of these markers might be more sensitive 
in detecting NK cells than CD56. For example, CD244 
(2B4) was consistently expressed on almost all NK cells 
at all time points. In contrast, a significant NK cell popu-
lation lacking the CD56 antigen could be detected up to 
day 150 after transplant ( fig. 2 a).
 Post-Transplant Reconstitution of KIR+/NKG2A–
NK Cells 
 As KIR+ NK cells contain the effectors of graft-versus-
leukemia reactions in haploidentical HSCT, we investi-
gated the kinetics of KIR+/NKG2A– NK cells which 
emerged after haploidentical HSCT in the CD56+ and the 
CD56– subsets. At the earliest time point (day 30), CD56–/
KIR+/NKG2A– NK cells outnumbered CD56+/KIR+/
NKG2A– NK cells (33.5  ! 10 6  8 22  ! 10 6 vs. 11  ! 10 6 
 8 9  ! 10 6 cells/l, p = 0.10). At all later time points the 
KIR+/NKG2A– NK cell count was higher in the CD56+ 
subset than in the CD56– subset, although the difference 
did not reach the level of statistical significance ( fig. 2 b). 
The KIR+/NKG2A– NK cell count peaked in both the 
CD56– (85  ! 10 6  8 120  ! 10 6 cells/l) and CD56+ NK 
cell subsets (136  ! 10 6  8 272  ! 10 6 cells/l, p = 0.49) on 
day 120 and declined thereafter.
 Functional Profile of CD56– NK Cells 
 To investigate CD56– NK cells functionally, we tested 
degranulation and cytokine production in response to 
stimulation with appropriate target cells.  Figure 3 a exem-
plifies degranulation as assessed by surface expression of 
CD107a after incubation with the HLA-deficient eryth-
roleukemia cell line K562 in CD56– and CD56 dim NK 
cells. In agreement with previously published data  [18] , 
activation of NK cells by co-incubation with K562 in 
transplant recipients was lower than that reported for 
healthy donor NK cells  [19] . Degranulation in CD56 dim 
NK cells (6  8 7%) was comparable to that of CD56– NK 
cells (5  8 6%, p = 0.26;  fig. 3 b). In contrast, IFN-  pro-
duction was significantly lower (3  8 3%) in CD56– NK 
cells compared to CD56 dim NK cells (4  8 5%, p = 0.007; 
 fig. 3 b) after exposure to K562 cells. However, both the 
degranulation and cytokine production assays suggested 
that CD56– respond to missing self-stimulation.
 In ADCC assays using a B cell line as target cell in con-
junction with the anti-CD20 antibody rituximab, 10  8 
5% of CD56 dim NK cells degranulated compared to 8  8 
5% of CD56– NK cells (p = 0.02). A similar trend was seen 
Table 1.  Immunophenotype of NK cells which reconstitute after 
T cell-depleted haploidentical transplantation
Antigen(s) CD56+
NK cells
CD56–
NK cells
p value
CD16 8389 82812 0.97
KIR 42821 46823 0.44
NKG2A 62824 33819 0.0001
KIR+/NKG2A– 38824 32825 0.02
NKp46 82819 55826 0.0001
NKp30 42821 35820 0.017
CD161 68827 58827 0.11
2B4 9981 89812 0.0001
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 Fig. 2. Post-transplant reconstitution of CD56+ and CD56– NK 
cells.  a Absolute numbers of CD56+ and CD56– NK cells (mean 
 8 SD) in the first 5 months after haploidentical HSCT.  b Post-
transplant reconstitution of KIR+/NKG2A– NK cells in CD56+ 
and CD56– subsets (mean  8 SD, n = 25). 
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for IFN-  production which was detected in 12  8 10% of 
CD56 dim NK cells compared to 8  8 6% of CD56– NK 
cells (p = 0.06;  fig. 3 e). No significant degranulation or 
cytokine production was measured for the CD56 bright NK 
cell subset in either assay  [20] .
 Alloreactivity of Clonally Expanded CD56+ and 
CD56– NK Cells 
 Cytotoxicity assays were performed with clonally ex-
panded NK cells against K562 and KIR ligand-mis-
matched allogeneic targets. Importantly, CD56– NK cells 
acquired CD56 expression during 15–20 days of stimula-
tion with IL-2, as has previously been shown for CD56– 
NK cells in HIV patients  [21] . The proliferative potential 
of CD56– versus CD56+ NK cells appeared to be similar 
as indicated by overlapping cloning efficiencies (mean 1 
cell in 300, p = 0.60) and number of cells obtained for each 
clone (range 2  ! 10 5 to 4  ! 10 5 ) in the two populations.
 Clones derived from CD56+ and CD56– NK cells ex-
erted similar cytotoxicity against K562: 50  8 10% vs. 44 
 8 17%, p = 0.37 ( fig. 4 a). Alloreactivity was further test-
ed against allogeneic targets lacking C1 or C2 expression. 
Lysis of PHA-lymphoblasts lacking HLA-C1 was compa-
rable in 63/383 NK clones derived from CD56+ NK cells 
(mean lysis 31  8 11%) and in 57/316 NK clones derived 
from CD56– NK cells (mean lysis 28  8 11%, p = 0.16; 
 fig. 4 b). In contrast, alloreactivity against allogeneic PHA 
lymphoblasts lacking HLA-C2 was weaker in 26/340 
CD56– NK clones (mean lysis 28  8 8%) compared to 
19/152 CD56+ NK clones (mean lysis 38  8 14%, p = 
0.007;  fig.  4 c). No alloreactive (cytotoxicity  1 5%) NK 
clones were detected against KIR ligand-matched targets.
 Cryopreserved acute myeloid leukemia blasts were 
also tested as targets. Alloreactivity against leukemia 
blasts lacking HLA-C1 was comparable (mean lysis 23  8 
4% in 6/96 CD56+ NK clones; mean lysis 21  8 2% in 
7/165 CD56– NK clones, p = 0.10;  fig. 4 d). Similarly, no 
significant differences were seen between CD56+ and 
CD56– NK cell clones in their capacity to lyse leukemia 
blasts lacking HLA-C2 (mean lysis 20  8 1%) in 3/107 
CD56– NK clones; and mean lysis 22  8 1% in 3/93 CD56+ 
NK clones, p = 0.65;  fig. 4 e).
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 Fig. 3. Functional profile of CD56– NK cells.  a Degranulation response (CD107a surface expression) of CD56– 
and CD56 dim NK cells after incubation with K562 target cells. CD107a expression and IFN-  production in 
CD56– and CD56 dim NK cells after incubation with K562 target cells ( b, c ), and after incubation with the EBV-
transformed B cell line in the presence of the anti-CD20 antibody (ADCC;  d, e ) (n = 9; mean  8 SD). 
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 Discussion 
 In healthy donors, the majority (approx. 90%) of NK 
cells are CD56 dim , whereas approximately 10% of NK cells 
are CD56 bright  [1] . NK cells lacking CD56 expression are 
rare in healthy donors, were originally described in HIV-
infected individuals  [21, 22] and have more recently been 
found at elevated levels in other chronic infectious dis-
eases, such as hepatitis C  [23, 24] and Chagas disease  [25] . 
However, in these settings, NK cells lacking CD56 expres-
sion are functionally defective as they display decreased 
levels of activating receptors and fail to kill target cells.
 The present study demonstrates that in recipients of T 
cell-depleted haploidentical HSCT, a significant number 
of reconstituting NK cells do not express CD56. We ob-
served a remarkable post-transplant expansion of these 
unusual CD56– NK cells. They express the natural cyto-
toxicity receptors NKp46 and NKp30 and activating co-
receptors such as CD244, lyse HLA-deficient target cells, 
express KIRs and show cytolytic activity against alloge-
neic targets and leukemic cells which do not express cog-
nate class I ligands. KIR expression occurs as a late event 
during NK cell development and NK cells expressing 
more than one KIR are among the most mature  [26, 27] . 
We found that NK cells expressing more than one KIR 
were preferentially CD56+. However, our data clearly 
show that CD56– NK cells are functional. When ana-
lyzed at the clonal level, the unusual CD3–/CD56– subset 
contained similar frequencies of alloreactive NK cells as 
the conventional CD3–/CD56+ subset.
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 Fig. 4. Cytolytic activities of clonally 
expanded CD56– versus CD56+ NK 
cells. Mean specific lysis of NK clones 
derived from CD56+ and CD56– NK 
cells against K562 target cells (a) and 
against allogeneic PHA lymphoblasts 
and leukemic target cells lacking ex-
pression of the HLA C1 and C2 speci-
ficities ( b–e ) (n = 15). 
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 An expansion of CD56– NK cells may be common to 
different forms of HSCT, as CD56–/CD16+ NK cells has 
previously been described after cord blood transplanta-
tion  [28] , and after HLA-matched bone marrow/periph-
eral blood stem cell transplantation  [29] . Little is known, 
however, about the function of CD56– NK cells arising 
after HSCT. Our data suggest that CD56– NK cells may 
contribute to graft-versus-leukemia effects after haplo-
identical and possibly other types of HSCT  [30] .
 Finally, the present data have a bearing on recent at-
tempts to assess the frequencies of potentially alloreactive 
NK cells by flow cytometry  [31] . Our data indicate that 
gating on conventional CD3–/CD56+ cells may consider-
ably underestimate the alloreactive NK cell frequency 
and that a gating strategy using a more broadly expressed 
receptor such as CD244 in combination with CD3 may be 
more appropriate.
 In conclusion, we show that in recipients of T cell-de-
pleted haploidentical HSCT, a significant number of NK 
cells lack expression of CD56. CD56– NK cells appear to 
be functional and capable of graft-versus-leukemia ef-
fects.
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